Peer-reviewedCC BYPharmaceutical biology
Protective effects of icariin in atherosclerotic cardiovascular disease: mechanistic basis, post-ischemic protection and translational limitations
4 affiliations
- 1Beijing University of Chinese Medicine , ,
- 2Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences , ,
- 3State Key Laboratory of Traditional Chinese Medicine Syndrome/National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences , ,
- 4Department of Geriatrics, Zhongshan Hospital of Traditional Chinese Medicine , ,
Related
- Natural Bioactive Agents as Adjunctive Candidates in Periodontitis: Mechanistic Links to Cardiovascular Disease and Translational Challenges
- Atherosclerotic plaque injury-mediated murine thrombosis models: advantages and limitations
- Revisiting the genetic support of leukotriene pathway drug targets in atherosclerotic cardiovascular disease.
- Impaired CD4+ T cell response to apolipoprotein B-100 peptide P210 in atherosclerotic cardiovascular disease is reversed by P210-conjugated nanoparticles
- Multivariate Genomic Analysis Reveals Shared Genetic Architecture and Potential Therapeutic Targets for Atherosclerotic Cardiovascular Disease
BibTeX
@article{wang2026protective,
title = {{Protective effects of icariin in atherosclerotic cardiovascular disease: mechanistic basis, post-ischemic protection and translational limitations}},
author = {Xuefei Wang and Zongliang Yu and Xiaoya Li and Lanqing Hu and Changxin Sun and Yajie Wang and Liang Li and Min Wu and Longtao Liu},
journal = {Pharmaceutical biology},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13656681},
note = {CC BY},
}
RIS
TY - JOUR
TI - Protective effects of icariin in atherosclerotic cardiovascular disease: mechanistic basis, post-ischemic protection and translational limitations
AU - Xuefei Wang
AU - Zongliang Yu
AU - Xiaoya Li
AU - Lanqing Hu
AU - Changxin Sun
AU - Yajie Wang
AU - Liang Li
AU - Min Wu
AU - Longtao Liu
PY - 2026
DA - 2026/10/16
JO - Pharmaceutical biology
UR - https://europepmc.org/article/PMC/PMC13656681
SN - 1388-0209
SN - 1744-5116
ER -